# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-193935
Filing Date
2026-04-30
Accepted
2026-04-30 07:02:39
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | defa14a_2025.htm | DEFA14A | 18061
2 | GRAPHIC | img243671806_0.jpg | GRAPHIC | 454550
3 | GRAPHIC | img243671806_1.jpg | GRAPHIC | 257517
| Complete submission text file | 0001193125-26-193935.txt |  | 999966

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41855 | Film No.: 26920002
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)